Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's
Brief Summary: The Standard Care versus Celecoxib Outcome Trial (SCOT) is a large streamline safety study designed to compare the cardiovascular safety of celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug (NSAID) therapy.Traditional NSAID's are associated with significant morbidity and mortality from gastrointestinal toxicity. Cyclooxygenase 2 (Cox-2)selective agents are associated with reduced upper gastrointestinal toxicity.Traditional NSAID's and Cox-2 inhibitors may also be associated with cardiovascular and renal disorders. Data from both randomised and observational studies suggest that celecoxib has similar or reduced cardiovascular toxicity when compared to traditional NSAID's. However, the overall safety balance of a strategy of celecoxib therapy versus a strategy of NSAID therapy is unknown. The European Medicines Evaluation Agency (EMEA) has requested that studies of the cardiovascular safety of celecoxib be carried out within the indicated population of Europe. This study addresses these issues by comparing the cardiovascular safety of celecoxib therapy with traditional NSAID therapy in the setting of the EU healthcare system.

As of May 2013, 7300 patients had been randomised, and had accrued an average 4.2 years of follow up by the end of May 2014.


Options:
A: Inclusion Criteria:

* All individuals age 50 to 70 years

Exclusion Criteria:

* Unable to give informed consent
* History of colorectal cancer
* History of adenomatous polyp
* History of inflammatory bowel disease
* Prior participation in FOBT screening
* Prior refusal to participate in FOBT screening
* Flexible sigmoidoscopy within the previous 3 years
* Virtual colonoscopy within the previous 3 years
* Optical colonoscopy within the previous 3 years
* Severe of terminal illness that would preclude benefit from colon cancer screening
B: Inclusion Criteria:

* Married women of reproductive age
* First pregnancy during time period of trial

Exclusion Criteria:

* Premenarchial girls
* Married women with a previous pregnancy enrolled into the trial
* Previously married women who have moved into the study area
* Single women (never married, widowers)
* Women who are sterilized (or whose husbands are sterilized)
* Menopausal women
C: Inclusion Criteria:

* Subjects 60 years or over Male \& Female
* Chronic NSAIDs use for 90 days or more in a 12 month period
* Subjects who have a licensed indication for chronic non-selective NSAID or Celecoxib.
* Eligible for treatment with either Celecoxib or alternative traditional non-selective NSAID.
* Subjects who are willing to consent to their paper and electronic medical records and prescribing data to be accessed.
* Subjects who are willing to be contacted and interviewed by trial investigators.

Exclusion Criteria:

* Established cardiovascular disease including ischaemic heart disease, Myocardial Infarction, angina or acute coronary syndrome, cerebrovascular disease or cerebrovascular accident or transient ischaemic attack, established peripheral vascular disease and moderate to severe heart failure.
D: Inclusion Criteria:

* Chinese American women had not had a mammography in the past 12 months
* Chinese American women had no personal history of breast cancer
* Chinese American women had no mammogram scheduled when enrolled

Exclusion Criteria:

* Non-Chinese Women
* Regular mammography users

Answer: C